Skip to content
Search

Latest Stories

Breast cancer may claim million lives per year by 2040: Lancet

Globally, breast cancer cases will increase from 2.3 million in 2020 to more than three million by 2040

Breast cancer may claim million lives per year by 2040: Lancet

BREAST CANCER is now the world's most common carcinogenic disease, with the ailment likely to cause a million deaths a year by 2040, , a new Lancet commission has found.

Around 7.8 million women were diagnosed with breast cancer in five years till the end of 2020 and about 685,000 women died from the disease the same year, it said.


Globally, breast cancer cases will increase from 2.3 million in 2020 to more than three million by 2040, with low- and middle-income countries being "disproportionately affected", the commission estimated.

By 2040, deaths due to the disease will be a million a year, it added.

The Lancet report pointed to "glaring inequities" and suffering from symptoms, despair and financial burden due to breast cancer, which are often "hidden and inadequately addressed".

Laying out recommendations for tackling these challenges in breast cancer, the commission suggested better communication between patients and health professionals as a crucial intervention that could improve quality of life, body image, and adherence to therapy, and positively impact survival.

"Women's fundamental human rights have historically been accorded lesser respect than men's in all settings, with implications for patient agency and autonomy," said Reshma Jagsi, Emory University School of Medicine, US.

"Every healthcare professional should receive some form of communication skills training. Improving the quality of communication between patients and health professionals, though seemingly simple, could have profound positive impacts that extend far beyond the specific setting of breast cancer management.

"Patients should be encouraged to exercise their voices, choosing their level of involvement in care decisions."

(PTI)

More For You

Mounjaro price rise

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro

iStock

Mounjaro’s highest dose to rise from £122 to £247.50, not £330

Highlights:

  • Eli Lilly had announced a steep price rise of up to 170% for Mounjaro.
  • A new discount deal with UK suppliers will limit the increase for patients.
  • Pharmacies will still apply a mark-up, but consumer costs are expected to rise less than initially feared.
  • NHS pricing remains unaffected due to separate arrangements.

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro, easing fears of a sharp rise in costs for UK patients. The new arrangement means that, from September, pharmacies and private services will face smaller wholesale increases than first expected, limiting the impact on consumers.

Why the price rise was announced

Earlier this month, Eli Lilly said it would raise Mounjaro’s list price by as much as 170%, which could have pushed the highest monthly dose from £122 to £330. The company argued that UK pricing needed to align more closely with higher costs in Europe and the United States.

Keep ReadingShow less
chicken-pox-istock

The Department of Health said the rollout would reduce missed days at nursery and school, cut time parents take off work, and save the NHS about £15 million a year. (Representational image: iStock)

iStock

England to introduce free chickenpox vaccine for children from 2026

CHILDREN in England will be offered a free chickenpox vaccine for the first time from January 2026, the government has announced.

GP practices will give eligible children a combined vaccine for measles, mumps, rubella and varicella (MMRV) as part of the routine childhood vaccination schedule. Around half a million children each year are expected to be protected.

Keep ReadingShow less
Naga Munchetty urges women to prioritise their health

Naga Munchetty

Naga Munchetty urges women to prioritise their health

WHEN broadcaster and journalist Naga Munchetty began speaking openly about her experiences with adenomyosis and debilitating menstrual pain, the response was overwhelming.

Emails and messages poured in from women who had endured years of dismissal, silence and shame when it came to their health. That outpouring became the driving force behind her new book, It’s Probably Nothing, which calls for women to be heard and to advocate for themselves in a medical system that has too often ignored them.

Keep ReadingShow less
London temple project for Shree Banke Bihari launched

London temple project for Shree Banke Bihari launched

Mahesh Liloriya

The Shree Kunj Bihari Vrindavan (UK) Temple has officially launched its project to establish a grand home for Shree Banke Bihari in London.

The inaugural event, held in Harrow from 4 pm, featured devotional chants, the Deep Pragtya ceremony, and a presentation outlining the temple’s vision. Speaking at the gathering, Shalini Bhargava described the planned temple as “a spiritual home promoting bhakti, unity and seva for generations to come.”

Keep ReadingShow less
Dickie and Watt

Dickie and Watt launched BrewDog at the age of 24

Getty Images

BrewDog co-founder Martin Dickie leaves after 17 years as James Watt steps back

Highlights:

  • Martin Dickie has announced his departure from BrewDog and the alcohol industry.
  • He co-founded the Ellon-based brewer with James Watt in 2007.
  • Dickie cited family time and personal reasons for his exit.
  • His departure follows recent bar closures as part of a company restructuring.
  • BrewDog confirmed no further leadership changes will follow.

BrewDog co-founder Martin Dickie has announced he is leaving the Scottish brewer and the wider alcohol industry for “personal reasons.” Dickie, who founded the Ellon-based business with James Watt in 2007, said he wanted to spend more time with his family after more than two decades in brewing and distilling.

Early beginnings

Dickie and Watt launched BrewDog at the age of 24, starting from a garage in Fraserburgh and selling hand-filled bottles from a van at local markets. The company grew rapidly to become one of the UK’s best-known craft brewers.

Keep ReadingShow less